You are here

Optimized Platforms for Proper Glycosylation and Sialylation of Recombinant Human Butyrylcholinesterase (rBChE)

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-20-P-0127
Agency Tracking Number: C192-007-0015
Amount: $167,499.12
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD192-007
Solicitation Number: 19.2
Timeline
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-04-10
Award End Date (Contract End Date): 2020-10-10
Small Business Information
1515 West 2200 South Suite F
Salt Lake City, UT 84119
United States
DUNS: 829431076
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Robert Price
 Principal Investigator
 (801) 915-7973
 robert@tekholding.com
Business Contact
 Anant Samudra
Phone: (801) 953-1047
Email: avsamudra@tekholding.com
Research Institution
N/A
Abstract

The threat of organophosphate (OP) chemical warfare agents (CWA) to United States military personnel is a persistent problem due to the relative ease of manufacturing chemical threats compared to nuclear and biological agents. Human butyrylcholinesterase (BChE) has been identified as a probable bio-scavenger of OP CWAs that could be used to protect individuals that could be exposed to OP CWAs. The goal of this project is to generate a mammalian cell line capable of expressing human BChE in tetrameric form with appropriate human glycosylation patterns . To achieve this goal we will utilize a triple pronged approach with multiple cell lines currently used to produce human therapeutic proteins. Each approach will be evaluated to determine technical and economic applicability to full scale manufacturing.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government